glp-1 alternatives GLP-TRIM - A Natural Alternative Tired of GLP-1s? Comparing Gastric

Market Share Projections Novo Nordisk itself forecasts that oral weight-loss drugs will capture more than one-third of the total GLP-1 market by 2030

These discoveries have further established obesity as a chronic, progressive biological disease requiring physiologic treatments beyond willful energy restriction and expenditure alone

Furthermore, continuous innovation in peptide stabilization and absorption technologies is enhancing drug performance

Physiology 2014

31,35-37 Prospective trials are needed to further explore this potential adverse event and worsened DR, which is the central premise of the ophthalmic FOCUS trial that is expected to release results in 2026